Impact of Delay of Treatment With Disease‐Modifying Antirheumatic Drugs in Psoriatic Arthritis: The CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Objective Our objective was to describe characteristics and compare clinical and patient‐reported outcomes (PROs) for disease‐modifying antirheumatic drug (DMARD)–naive patients with psoriatic arthritis (PsA) who initiate DMARD therapy early versus late. Methods Patients with PsA from the CorEvitas...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | ACR Open Rheumatology |
| Online Access: | https://doi.org/10.1002/acr2.70019 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|